Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases

Drug Discovery Today

Volumn 11, Issue 13-14, 2006, Pages 646-654

  Reddy, V Prakash ^a   Beyaz, Ayse ^a  

^a MISSOURI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 4 OXO N PHENYL 4,5 DIHYDRO 2 [(1 METHYLETHYLIDENE)HYDRAZINO] 5 THIAZOLEACETAMIDE; ACETAMIDE DERIVATIVE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT BREAKER; ADVANCED GLYCATION END PRODUCT INHIBITOR; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ALT 946; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BLOCKING AGENT; BROMINE DERIVATIVE; CAN C; CARNOSINE; CLIOQUINOL; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCARNOSINE; IRON CHELATING AGENT; METFORMIN; N [[2 (HYDRAZINOIMINOMETHYL)AMINO]ETHYL]ACETAMIDE; N ACETYLCARNOSINE; N PHENACYL 1,3 THIAZOLIUM BROMIDE; NIFEDIPINE; PERINDOPRIL; PRODRUG; PYRIDORIN; PYRIDOXAMINE; SOLUBLE ADVANCED GLYCATION END PRODUCT RECEPTOR; TENILSETAM; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTHRITIS; ATHEROGENESIS; ATHEROSCLEROSIS; CATARACT; CATARACTOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETOGENESIS; DRUG MECHANISM; GLYCATION; HUMAN; HYPERTENSION; INFLAMMATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OSTEOARTHRITIS; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PYRIDOXINE DEFICIENCY; REDUCTION; REVIEW; RIGIDITY; VASCULAR DISEASE;

AGING; ANIMALS; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; HYPOGLYCEMIC AGENTS; MAILLARD REACTION; METFORMIN; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC;

EID: 33745190013     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.05.016     Document Type: Review

References (110)

1. Maillard L.C. Action of amino acids on sugars. Formation of melanoidins in a methodical way. Compt. Rend. 154 (1912) 66-68
2. Thomas M.C., et al. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr. Drug Targets 6 (2005) 453-474
3. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 67 (2005) 3-21
4. Reddy V.P., et al. Involvement of Maillard reactions in Alzheimer disease. Neurotox. Res. 4 (2002) 191-209
5. Rojas A., and Morales M.A. Advanced glycation and endothelial functions: A link towards vascular complications in diabetes. Life Sci. 76 (2004) 715-730
6. Kikuchi S., et al. Glycation-a sweet tempter for neuronal death. Brain Res. Brain Res. Rev. 41 (2003) 306-323
7. Monnier V.M. Intervention against the Maillard reaction in vivo. Arch. Biochem. Biophys. 419 (2003) 1-15
8. Yim M.B., et al. Protein glycation: creation of catalytic sites for free radical generation. Ann. N. Y. Acad. Sci. 928 (2001) 48-53
9. Cerami C., et al. Tobacco smoke is a source of toxic reactive glycation products. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13915-13920
10. Nicholl I.D., and Bucala R. Advanced glycation end products and cigarette smoking. Cell. Mol. Biol. 44 (1998) 1025-1033
11. Vlassara H. Advanced glycation in health and disease: Role of the modern environment. Ann. N. Y. Acad. Sci. 1043 (2005) 452-460
12. Dickerson T.J., and Janda K.D. A previously undescribed chemical link between smoking and metabolic disease. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 15084-15088
13. Katz J., et al. Receptor for advanced glycation end product (RAGE) upregulation in human gingival fibroblasts incubated with nornicotine. J. Periodontol. 76 (2005) 1171-1174
14. Hein G.E., et al. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol. Int. 26 (2005) 137-141
15. Miyata T., et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem. Biophys. Res. Commun. 244 (1998) 45-49
16. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15 (1992) 1835-1843
17. Takeuchi M., et al. Advanced glycation end product (AGE) inhibitors and their therapeutic implications in diseases. Int. J. Clin. Pharmacol. Res. 24 (2004) 95-101
18. Dyer D.G., et al. Formation of pentosidine during nonenzymic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem. 266 (1991) 11654-11660
19. Chellan P., and Nagaraj R.H. Early glycation products produce pentosidine cross-links on native proteins: novel mechanism of pentosidine formation and propagation of glycation. J. Biol. Chem. 276 (2001) 3895-3903
20. Wilker S.C., et al. Chromatographic quantification of argpyrimidine, a methylglyoxal-derived product in tissue proteins: Comparison with pentosidine. Anal. Biochem. 290 (2001) 353-358
21. Yoshida N., et al. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 54 (2005) 345-350
22. Nagaraj R.H., and Sady C. The presence of a glucose-derived Maillard reaction product in the human lens. FEBS Lett. 382 (1996) 234-238
23. Castellani R.J., et al. Advanced glycation modification of Rosenthal fibers in patients with Alexander disease. Neurosci. Lett. 231 (1997) 79-82
24. Chellan P., and Nagaraj R.H. Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Arch. Biochem. Biophys. 368 (1999) 98-104
25. Franke S., et al. Increased levels of advanced glycation end products in human cataractous lenses. J. Cataract Refract. Surg. 29 (2003) 998-1004
26. ε-(Carboxymethyl) lysine and hexitol-lysine. Free Radic. Biol. Med. 31 (2001) 175-180
27. Thornalley P.J. Dicarbonyl intermediates in the Maillard reaction. Ann. N. Y. Acad. Sci. 1043 (2005) 111-117
28. Biemel K.M., et al. Identification and quantification of major Maillard cross-links in human serum albumin and lens protein. Evidence for glucosepane as the dominant compound. J. Biol. Chem. 277 (2002) 24907-24915
29. Biemel K.M., et al. Formation pathways for lysine-arginine cross-links derived from hexoses and pentoses by Maillard processes. Unraveling the structure of a pentosidine precursor. J. Biol. Chem. 276 (2001) 23405-23412
30. Lederer M.O., and Klaiber R.G. Cross-linking of proteins by Maillard processes: characterization and detection of lysine-arginine cross-links derived from glyoxal and methylglyoxal. Bioorg. Med. Chem. 7 (1999) 2499-2507
31. Sell D.R., et al. Glucosepane Is a Major Protein Cross-link of the Senescent Human Extracellular Matrix: Relationship with Diabetes. J. Biol. Chem. 280 (2005) 12310-12315
32. Stitt A.W. The Maillard reaction in eye diseases. Ann. N. Y. Acad. Sci. 1043 (2005) 582-597
33. Forbes J.M., et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53 (2004) 1813-1823
34. Yamamoto Y., et al. Receptor for advanced glycation end products is a promising target of diabetic nephropathy. Ann. N. Y. Acad. Sci. 1043 (2005) 562-566
35. ε-(carboxymethyl)lysine in hippocampal CA4 pyramidal neurons of aged human brain. Pathol. Int. 52 (2002) 563-571
36. Sayre L.M., et al. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. 8 (2001) 721-738
37. Smith M.A., et al. Amyloidosis, advanced glycation end products and Alzheimer disease. Comments. Neuroreport 6 (1995) 1595
38. Sasaki N., et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol. 153 (1998) 1149-1155
39. Argirov O.K., et al. Phototransformations of advanced glycation end products in the human eye lens due to ultraviolet A light irradiation. Ann. N. Y. Acad. Sci. 1043 (2005) 166-173
40. Smith M.A., et al. Oxidative posttranslational modifications in Alzheimer's disease: a possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Mol. Chem. Neuropathol. 28 (1996) 41-48
41. Munch G., et al. Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease. Brain Res. 796 (1998) 307-310
42. Kuhla B., et al. Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease. Ann. N. Y. Acad. Sci. 1043 (2005) 211-216
43. Thomas M.C., et al. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr. Drug Targets 6 (2005) 453-474
44. Mohamed A.K., et al. The role of oxidative stress and NF-κB activation in late diabetic complications. Biofactors 10 (1999) 157-167
45. Schmidt A.M., et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84 (1999) 489-497
46. Zieman S.J., and Kass D.A. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 64 (2004) 459-470
47. Bierhaus A., et al. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83 (2005) 876-886
48. Yamagishi S., et al. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders. Med. Hypotheses 65 (2005) 392-394
49. Gugliucci A., and Bendayan M. Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39 (1996) 149-160
50. Miyata T., et al. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int. 53 (1998) 416-422
51. Saito A., et al. Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases. Ann. N. Y. Acad. Sci. 1043 (2005) 637-643
52. Wendt T.M., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162 (2003) 1123-1137
53. Hudson B.I., et al. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch. Biochem. Biophys. 419 (2003) 80-88
54. Takahashi M., et al. Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Br. J. Rheumatol. 36 (1997) 637-642
55. Newkirk M.M., et al. Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Res. Ther. 5 (2003) R82-R90
56. Hart D.J., et al. Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford Study. Arthritis Rheum. 42 (1999) 17-24
57. DeGroot J., et al. Accumulation of Advanced Glycation End Products Decreases Collagen Turnover by Bovine Chondrocytes. Exp. Cell Res. 266 (2001) 303-310
58. Felson D.T., and Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 41 (1998) 1343-1355
59. Creamer P., and Hochberg M.C. Osteoarthritis. Lancet 350 (1997) 503-508
60. Verzijl N., et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J. Biol. Chem. 275 (2000) 39027-39031
61. Verzijl N., et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem. J. 350 (2000) 381-387
62. El Khoury J., et al. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J. Biol. Chem. 269 (1994) 10197-10200
63. Vlassara H., et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol. Med. 1 (1995) 634-646
64. Li Y.M., et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11047-11052
65. Ohgami N., et al. CD36, serves as a receptor for advanced glycation endproducts (AGE). J. Diabetes Complications 16 (2002) 56-59
66. Ramasamy R., et al. Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15 (2005) 16R-28R
67. Pullerits R., et al. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res. Ther. 7 (2005) R817-R824
68. Mjalli, A.M.M. et al. (2005) RAGE antagonists as agents to reverse amyloidosis and associated diseases. Patent No. 2004-US16104; Chem. Abstr. 2005:14210
69. Mullarkey C.J., et al. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem. Biophys. Res. Commun. 173 (1990) 932-939
70. Yamamoto Y., et al. Receptor for advanced glycation end products is a promising target of diabetic nephropathy. Ann. N. Y. Acad. Sci. 1043 (2005) 562-566
71. Shuvaev V.V., et al. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol. Aging 22 (2001) 397-402
72. Min C., et al. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diabetes Res. Clin. Pract. 46 (1999) 197-202
73. Stopper H., et al. Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett. 190 (2003) 151-156
74. Lue L.F., et al. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 249-266
75. Basta G., et al. At Least 2 Distinct Pathways Generating Reactive Oxygen Species Mediate Vascular Cell Adhesion Molecule-1 Induction by Advanced Glycation End Products. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1401-1407
76. Nawroth P., et al. Atherosclerosis and restenosis: Is there a role for RAGE? Curr. Diab. Rep. 5 (2005) 11-16
77. Basta G., et al. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 63 (2004) 582-592
78. Schmidt A.M., et al. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 1498 (2000) 99-111
79. Moreira P.I., et al. Oxidative stress and neurodegeneration. Ann. N. Y. Acad. Sci. 1043 (2005) 545-552
80. Zhu X., et al. Oxidative stress signalling in Alzheimer's disease. Brain Res. 1000 (2004) 32-39
81. Colaco C.A.L.S., and Harrington C.R. Inhibitors of the Maillard reaction: potential in the treatment of Alzheimer's disease. CNS Drugs 6 (1996) 167-177
82. Blakytny R., and Harding J.J. Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Exp. Eye Res. 54 (1992) 509-518
83. Stadler K., et al. Beneficial effects of aminoguanidine on the cardiovascular system of diabetic rats. Diabetes Metab. Res. Rev. 21 (2005) 189-196
84. Bolton W.K., et al. Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy. Am. J. Nephrol. 24 (2004) 32-40
85. Miyata T., and van Ypersele de Strihou C. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch. Biochem. Biophys. 419 (2003) 50-54
86. Shaw R.J., et al. The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin. Science 310 (2005) 1642-1646
87. Battah S., et al. Kinetics and mechanism of the reaction of metformin with methylglyoxal. Int. Congr. Ser. 1245 (2002) 355-356
88. Booth A.A., et al. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J. Biol. Chem. 272 (1997) 5430-5437
89. Metz T.O., et al. Pyridoxamine Traps Intermediates in Lipid Peroxidation Reactions in vivo: Evidence on the Role of Lipids in Chemical Modification of Protein and Development of Diabetic Complications. J. Biol. Chem. 278 (2003) 42012-42019
90. Voziyan P.A., and Hudson B.G. Pyridoxamine as a multifunctional pharmaceutical: Targeting pathogenic glycation and oxidative damage. Cell. Mol. Life Sci. 62 (2005) 1671-1681
91. Williams Mark E. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr. Diab. Rep. 4 (2004) 441-446
92. Voziyan P.A., and Hudson B.G. Pyridoxamine: The many virtues of a Maillard reaction inhibitor. Ann. N. Y. Acad. Sci. 1043 (2005) 807-816
93. Hipkiss A.R., et al. Non-enzymic glycosylation of the dipeptide L-carnosine, a potential anti-protein-crosslinking agent. FEBS Lett. 371 (1995) 81-85
94. Babizhayev M.A., et al. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R D. 5 (2004) 125-139
95. Carini M., et al. Acrolein-sequestering ability of endogenous dipeptides: Characterization of carnosine and homocarnosine/acrolein adducts by electrospray ionization tandem mass spectrometry. J. Mass Spectrom. 38 (2003) 996-1006
96. Doraiswamy P.M., and Finefrock A.E. Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol. 3 (2004) 431-434
97. Youdim M.B.H., et al. The pivotal role of iron in NF-kB activation and nigrostriatal dopaminergic neurodegeneration: Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann. N. Y. Acad. Sci. 890 (1999) 7-25
98. Price D.L., et al. Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 276 (2001) 48967-48972
99. Mizutani K., et al. Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J. Hypertens. 20 (2002) 1607-1614
100. Tikellis C., et al. Role of the renin-angiotensin system in the endocrine pancreas: Implications for the development of diabetes. Int. J. Biochem. Cell Biol. 38 (2006) 737-751
101. Forbes J.M., et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 16 (2005) 2363-2372
102. Wittmann I., et al. Prevention and treatment of diabetic nephropathy. Diabetes Res. Clin. Pract. 68 Suppl. 1 (2005) S36-S42
103. Hughes D.B., and Britton M.L. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Pharmacotherapy 25 (2005) 1602-1620
104. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens. 21 (2003) 3-12
105. Yang S., et al. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch. Biochem. Biophys. 412 (2003) 42-46
106. DeGroot J. The AGE of the matrix: chemistry, consequence and cure. Curr. Opin. Pharmacol. 4 (2004) 301-305
107. Vasan S., et al. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch. Biochem. Biophys. 419 (2003) 89-96
108. Kass D.A., et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104 (2001) 1464-1470
109. Little W.C., et al. The Effect of Alagebrium Chloride (ALT-711), a Novel Glucose Cross-Link Breaker, in the Treatment of Elderly Patients With Diastolic Heart Failure. J. Card. Fail. 11 (2005) 191-195
110. Bakris G.L., et al. Advanced glycation end-product cross-link breakers: A novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens. 17 (2004) 23S-30S